XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Schedule of Disaggregated Revenue

For the three months ended March 31, 2021 and 2020, the Company had the following disaggregated revenue:

 

    Three Months Ended March 31,  
    2021     %     2020     %  
Product revenues by Brand for Conversion Labs PR:                                
Shapiro MD   $ 3,383,783       19 %   $ 2,337,108       54 %
Rex MD     9,840,553       54 %     492,773       11 %
iNR Wellness     23,905       - %     69,928       2 %
Purpurex     35,074       - %     53,522       1 %
Scarology     -       - %     2,470       - %
                                 
Total product revenue for Conversion Labs PR   $ 13,283,315       73 %   $ 2,955,801       69 %
                                 
Software revenue for LegalSimpli     4,914,797       27 %     1,349,011       31 %
                                 
Total net revenue   $ 18,198,112       100 %   $ 4,304,812       100 %
Summary of Inventory

As of March 31, 2021 and December 31, 2020, the Company’s inventory consisted of the following:

 

    March 31,     December 31,  
    2021     2020  
             
Finished Goods - Products   $ 1,616,268       1,172,624  
Raw materials and packaging components     115,594       149,115  
Inventory reserve     (57,481 )     (57,481 )
Total Inventory - net   $ 1,674,381     $ 1,264,258  
Schedule of Potentially Dilutive Securities

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price could be less than the average market price of the common shares:

 

   

Three Months

Ended

   

Three Months

Ended

 
    March 31,     March 31,  
    2021     2020  
             
Series B Preferred Stock     1,076,923       -  
Restricted Stock Units (RSUs)     47,500       -  
Stock options     4,395,000       3,869,000  
Warrants     3,550,471       2,926,636  
Potentially dilutive securities     9,069,894       6,795,636